OTCMKTS:MLNTQ Melinta Therapeutics (MLNTQ) Stock Price, News & Analysis $0.11 0.00 (0.00%) As of 04/20/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Melinta Therapeutics Stock (OTCMKTS:MLNTQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Melinta Therapeutics alerts:Sign Up Key Stats Today's Range$0.11▼$0.1150-Day Range$0.11▼$0.1152-Week Range$0.06▼$8.60Volume32,900 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMelinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More… Receive MLNTQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLNTQ Stock News HeadlinesMelinta Therapeutics Inc (MLNTQ)April 10, 2025 | uk.investing.comMelinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes EventNovember 30, 2022 | yahoo.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. June 2, 2025 | Porter & Company (Ad)Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022October 18, 2022 | benzinga.comNexus loses generic drug approval thanks to contactless FedEx deliveryOctober 10, 2022 | reuters.comRain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in LiposarcomaAugust 4, 2022 | finance.yahoo.comMelinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American TherapeuticsApril 6, 2022 | finance.yahoo.comMelinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical AffairsMarch 14, 2022 | finance.yahoo.comSee More Headlines MLNTQ Stock Analysis - Frequently Asked Questions How have MLNTQ shares performed this year? Melinta Therapeutics' stock was trading at $0.11 at the beginning of 2025. Since then, MLNTQ shares have increased by 0.0% and is now trading at $0.11. View the best growth stocks for 2025 here. How do I buy shares of Melinta Therapeutics? Shares of MLNTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:MLNTQ CIKN/A Webwww.melinta.com Phone908-617-1309FaxN/AEmployees290Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:MLNTQ) was last updated on 6/2/2025 by MarketBeat.com Staff From Our PartnersThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Melinta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.